Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts

Blood

Volumn 100, Issue 1, 2002, Pages 318-326

  Sandmaier, Brenda M ^a,b,c,d   Bethge, Wolfgang A ^a,b,c,d   Scott Wilbur, D ^a,b,c,d   Hamlin, Donald K ^a,b,c,d   Santos, Erlinda B ^a,b,c,d   Brechbiel, Martin W ^a,b,c,d   Fisher, Darrell R ^a,b,c,d   Storb, Rainer ^a,b,c,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIBODY CONJUGATE; BISMUTH 213; CD45 ANTIBODY; CYCLOHEXYL A; CYCLOSPORIN; IODINE 123; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTETIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; GAMMA IRRADIATION; IMMUNOSUPPRESSIVE TREATMENT; ISOTOPE LABELING; MORTALITY; NONHUMAN; PRIORITY JOURNAL; WHOLE BODY RADIATION;

EID: 0036660169     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-12-0322     Document Type: Article

References (68)

1. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048-3054.
2. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
3. Macklis RM. Radioisotope-mediated purging in bone marrow transplantation. Prog Clin Biol Res. 1990;333:109-119.
4. Matthews DC, Appelbaum FR, Press OW, Eary JF, Bernstein ID. The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies. Cancer Treat Res. 1997;77:121-139.
5. Matthews DC, Appelbaum FR, Eary JF, et al. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. Blood. 1991;78:1864-1874.
6. 131I-anti-CD45 antibody plus cyclophosphamide and total-body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237-1247.
7. Fisher DR. α-particle emitters in medicine. In: Adelstein SJ, Kassis AI, Burt RW, eds. Dosimetry of Administered Radionuclides. Washington, DC: American College of Nuclear Physicians; 1989:194-214.
8. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with α-emitting nuclides. Eur J Nucl Med. 1998;25:1341-1351.
9. Wilbur DS. Potential use of α-emitting radionuclides in the treatment of cancer. Antibody Immunoconjugates Radiopharm. 1991;4:85-97.
10. Zalutsky MR, Bigner DD. Radioimmunotherapy with α-particle emitting radioimmunoconjugates. Acta Oncol. 1996;35:373-379.
11. Macklis RM, Kinsey BM, Kassis Al, et al. Radioimmunotherapy with α-particle-emitting immunoconjugates. Science. 1988;240:1024-1026.
12. Raju MR, Eisen Y, Carpenter S, Inkret WC, Radiobiology of α particles, III: cell inactivation by α-particle traversals of the cell nucleus. Radiat Res. 1991;128:204-209.
13. Abbas Rizvi SM, Sarkar S, Goozee G, Allen BJ. Radioimmunoconjugates for targeted α therapy of malignant melanoma. Melanoma Res. 2000;10:281-289.
14. Adams GP, Shaller CC, Chappell LL, et al. Delivery of the α-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol. 2000;27:339-346.
15. 212bismuth, chelated to a monoclonal antibody. Antibody Immunoconjugates Radiopharm. 1988;1:43-53.
16. Huneke RB, Pippin CG, Squire RA, Brechbiel MW, Gansow OA, Strand M. Effective α-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res. 1992;52:5818-5820.
17. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095-6100.
18. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators, Science. 2001;294:1537-1540.
19. 213Bi-HuM 195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999;40: 1935-1946.
20. Zalutsky MR, Akabani G, Cokgor I, et al. Phase I trial of astatine-211 labeled human/mouse chimeric anti-tenascin antibody administered into malignant brain tumor resection cavities [abstract]. Neuro-oncology 1999;1:S65-S66.
21. Omary MB, Trowbridge IS, Battifora HA. Human homologue of murine T200 glycoprotein. J Exp Med. 1980;152:842-852.
22. Wu C, Kobayashi H, Sun B, et al. Stereochemical influence on the stability of radio-metal complexes in vivo: synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-Cy-DTPA. Bioorg Med Chem. 1997;5:1925-1934.
23. Wagner JL, Burnett RC, DeRose SA, Francisco LV, Storb R, Ostrander EA. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation. 1996;62:876-877.
24. Wagner JL, Works JD, Storb R. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. Tissue Antigens. 1998;52:397-401.
25. Caniatti M, Roccabianca P, Scanziani E, Paltrinieri S, Moore PF. Canine lymphoma: immunocytochemical analysis of fine-needle aspiration biopsy. Vet Pathol. 1996;33:204-212.
26. Moore PF, Rossitto PV, Danilenko DM, Wielenga JJ, Raff RF, Severns E. Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high-density expression of CD4 by canine neutrophils. Tissue Antigens. 1992;40:75-85.
27. Barsoukov AA, Moore PF, Storb R, Santos EB, Sandmaier BM. The use of an anti-TCR α β monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation. 1999;67:1329-1335.
28. Sandmaier BM, Storb R, Appelbaum FR, Gallatin WM. An antibody that facilitates hematopoietic engraftment recognizes CD44. Blood. 1990;76:630-635.
29. Sandmaier BM, Schuening FG, Blanco JA, et al. Biochemical characterization of a unique canine myeloid antigen. Leukemia. 1991;5:125-130.
30. Denkers EY, Badger CC, Ledbetter JA, Bernstein ID. Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol. 1985;135:2183-2186.
31. Jacobsen CN, Aasted B, Broe MK, Petersen JL. Reactivities of 20 anti-human monoclonal antibodies with leucocytes from ten different animal species. Vet Immunol Immunopathol. 1993;39:461-466.
32. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem. 1992;3:342-345.
33. Sandmaier BM, Storb R, Bennett KL, Appelbaum FR, Santos EB. Epitope specificity of CD44 for monoclonal antibody-dependent facilitation of marrow engraftment in a canine model. Blood. 1998;91:3494-3502.
34. Raff RF, Deeg HJ, Farewell VT, DeRose S, Storb R. The canine major histocompatibility complex: population study of DLA-D alleles using a panel of homozygous typing cells. Tissue Antigens. 1983;21:360-373.
35. Loughran TP Jr, Deeg HJ, Storb R. Morphologic and phenotypic anatysis of canine natural killer cells: evidence for T-cell lineage. Cell Immunol. 1985;95:207-217.
36. Storb R, Raff RF, Graham T, et al. Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. Int J Radiat Oncol Biol Phys. 1993;26:275-283.
37. 131I-labeled antimyeloid antibody in normal dogs: effects of a "cold" antibody pretreatment dose on marrow localization. Exp Hematol. 1989;17:929-934.
38. Ladiges WC, Storb R, Thomas ED. Canine models of bone marrow transplantation. Lab Anim Sci. 1990;40:11-15.
39. Yu C, Ostrander E, Bryant E, Burnett R, Storb R. Use of (CA)n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation. 1994;58:701-706.
40. 32P-postlabeling assay. Carcinogenesis. 1992;13:1475-1479.
41. Matthews DC, Badger CC, Fisher DR, et al. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Cancer Res. 1992; 52:1228-1234.
42. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood. 2001;98:565-572.
43. 131I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models. Cancer Res. 2001;61:5126-5131.
44. 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res. 1999;59:2635-2643.
45. 213Bi. Nucl Med Biol. 1999;26:149-157.
46. 213Bi, and their decay chain related radionuclides, for therapeutic applications. Chem Rev. 2001;101:2019-2036.
47. Andres TL, Kadin ME. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol. 1983;79:546-552.
48. Caldwell CW, Patterson WP, Hakami N. Alterations of HLe-1 (T200) fluorescence intensity on acute lymphoblastic leukemia cells may relate to therapeutic outcome. Leuk Res. 1987;11:103-106.
49. Trowbridge IS, Thomas ML. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol. 1994;12:85-116.
50. Tiffany LJ, Dobbs D, Garmestani K. Radiolabeled CHXB-2E4 is stable in vivo and is a suitable immunoconjugate for testing a-particle-emitting bismuth radionuclides in interleukin-2 receptor targeted immunotherapy. Antibody Immunoconjugates Radiopharm. 1994;7:99-115.
51. Milenic DE, Roselli M, Mirzadeh S, et al. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. Cancer Biother Radiopharm. 2001;16:133-146.
52. Nikula TK, McDevitt MR, Finn RD, et al. α-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med. 1999:40:166-176.
53. Kobayashi H, Wu C, Yoo TM, et al. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies. J Nucl Med. 1998;39:829-836
54. Jurcic JG. Antibody therapy for residual disease in acute myelogenous leukemia. Crit Rev Oncol Hematol. 2001;38:37-45.
55. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 1990;50:4221-4226.
56. Prickett TC, McKenzie JL, Hart DN. Characterization of interstitial dendritic cells in human liver. Transplantation. 1988;46:754-761.
57. Mehal WZ,Azzaroli F, Crispe IN. Immunology of the healthy liver: old questions and new insights. Gastroenterology. 2001;120:250-260.
58. Johansson AG, Lovdal T, Magnusson KE, Berg T, Skogh T. Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology. 1996;24:169-175.
59. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92:406-413.
60. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction following gemtuzumab ozogamicin (Mylotarg). Blood. 2002;99:2310-2314.
61. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radial Oncol Biol Phys. 1995;31:1237-1248.
62. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (venocclusive disease). Semin Liver Dis. 2002;22:27-41.
63. Wielockx B, Lannoy K, Shapiro SD, et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med. 2001;7:1202-1208.
64. Wang X, Kanel GC, DeLeve LD. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology. 2000;31:428-434.
65. DeLeve LD, Wang X, Tsai J, Kanel G, Tokes Z. Prevention of hepatic venocclusive disease in the rat by inhibition of matrix metalloproteinases [abstract]. Gastroenterology. 2001;120:A54.
66. Knox SJ. Overview of studies on experimental radioimmunotherapy. Cancer Res. 1995;55;5832S-5836S.
67. Weiner LM. Monoclonal antibody therapy of cancer. Semin Oncol. 1999;26:43-51.
68. Jurcic JG, McDevitt MR, Sgouros G, et al. Phase I trial of targeted α-particle therapy for myeloid leukemias with bismuth-213-HuM195 (Anti-CD33) [abstract]. J Clin Oncol. 1999;18:7a.